B. Schwartz

发表

The burden of illness associated with renal cell carcinoma in the United States.

D. Thompson, K. Lang, N. Danchenko, 2007, Urologic oncology.

Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC).

C. Porta, J. Bruix, A. Santoro, 2016 .

Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma

P. Hainaut, T. Decaens, P. Marche, 2018, Oncotarget.

Efficacy Analysis for Molecular Subgroups in MARQUEE: a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Tivantinib (ARQ 197) Plus Erlotinib versus Placebo plus Erlotinib in Previously Treated Patients with Locally Advanced or Metastatic, Non-squamous, Non-small Cell Lung Cancer (NSCLC

G. Scagliotti, L. Sequist, F. Shepherd, 2014 .

Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study.

J. Sosman, I. Puzanov, A. Santoro, 2012 .

A randomized, placebo-controlled, phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy.

S. Barni, L. Hart, J. Bendell, 2013 .

Mecillinam Activity Compared to Ampicillin, Trimethoprim/Sulfamethoxazole, Ciprofloxacin and Nitrofurantoin against Urinary Tract Isolates of Gram-Negative Bacilli

J. Karlowsky, D. Hoban, G. Zhanel, 1998, Chemotherapy.

Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma

A. Gasbarrini, C. Porta, A. Santoro, 2017, Oncotarget.

Phase Ib dose-escalation trial evaluating c-MET inhibitor ARQ 197 administered in combination with gemcitabine to patients (pts) with advanced solid tumors.

Suzanne F. Jones, J. Bendell, L. Camacho, 2010 .

Derazantinib (DZB) provides antitumor efficacy regardless of line of therapy in patients (pts) with FGFR2-fusion positive advanced intrahepatic cholangiocarcinoma (iCCA).

V. Mazzaferro, S. Braun, K. Papadopoulos, 2019, Journal of Clinical Oncology.

A Phase I Clinical Trial of Darinaparsin in Patients with Refractory Solid Tumors

C. Ng, R. Kurzrock, S. Verstovsek, 2009, Clinical Cancer Research.

ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations.

V. Mazzaferro, K. Papadopoulos, L. Rimassa, 2017 .

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

V. Mazzaferro, F. D. De Braud, K. Papadopoulos, 2018, British Journal of Cancer.

c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.

G. Gibney, R. Camp, H. Kluger, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis

J. Bruix, N. Senzer, A. Santoro, 2013, British Journal of Cancer.

Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor–associated tumors

G. Demetri, N. Senzer, I. Judson, 2012, Cancer.

In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)

C. Simone, S. Di Tommaso, A. Selicorni, 2018, neurogenetics.

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy

S. Barni, L. Hart, J. Bendell, 2016, International journal of cancer.

A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors

N. Senzer, T. Mekhail, L. Rosen, 2011, Clinical Cancer Research.

Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.

A. Adjei, B. Schwartz, E. Garmey, 2011, The oncologist.

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours

A. Tolcher, K. Papadopoulos, D. Rasco, 2017, British Journal of Cancer.

Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

M. Ratain, K. Flaherty, M. Gore, 2005 .

Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

R. Bukowski, W. Stadler, B. Schwartz, 2005 .

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

C. Porta, V. Mazzaferro, J. Bruix, 2018, The Lancet. Oncology.

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

A. Gasbarrini, C. Porta, H. Van Vlierberghe, 2016, Oncotarget.

IClinicalTrial of Darinaparsin in Patients with Refractory SolidTumors

C. Ng, R. Kurzrock, S. Verstovsek, 2009 .

A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.

Suzanne F. Jones, Yulei N. Wang, J. Bendell, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

V. Mazzaferro, K. Papadopoulos, L. Rimassa, 2018, British Journal of Cancer.

Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure.

H. Krum, M. Packer, M. Kukin, 1995, Circulation.

Organic arsenic in patients (pts) with advanced solid tumors: Phase-1 results of zio-101 (s-dimethylarsino-glutathione)

R. Kurzrock, L. Camacho, D. Hong, 2007 .

Antimicrobial resistance and clinical effectiveness of co-trimoxazole versus amoxycillin for pneumonia among children in Pakistan: randomised controlled trial. Pakistan Co-trimoxazole Study Group.

W. Straus, S. Qazi, B. Schwartz, 1998, Lancet.

c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.

G. Gibney, R. Camp, H. Kluger, 2013 .

Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIV-HCC phase III trial.

C. Porta, V. Mazzaferro, J. Bruix, 2017 .

Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors.

A. Tolcher, P. LoRusso, K. Papadopoulos, 2015 .

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors

J. Sosman, I. Puzanov, A. Santoro, 2014, Investigational New Drugs.

A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.

Y. Wang, J. Bendell, L. Camacho, 2014 .

Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: Results of a randomized controlled phase II trial (RCT).

A. Gasbarrini, C. Porta, A. Santoro, 2012 .

Phase Ib results of c-MET inhibitor ARQ 197 in combination with gemcitabine in a cohort of patients (pts) with advanced breast, ovarian, and uterine tumors.

J. Bendell, L. Camacho, G. Abbadessa, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma

C. Porta, J. Bruix, A. Santoro, 2017, World journal of gastroenterology.

Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications

V. Mazzaferro, S. Braun, K. Papadopoulos, 2019, Annals of Oncology.

Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with NRAS wild-type or mutant melanoma from a phase I study.

J. Sosman, I. Puzanov, W. Ma, 2012 .

ZIO-101 (S-dimethylarsino-glutathione): Phase I/II trials in advanced/progressive multiple myeloma

A. Belch, D. Reece, S. Jaganath, 2007 .

C-met as a therapeutic target using ARQ 197 in renal cell carcinoma.

G. Gibney, R. Camp, H. Kluger, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final results from ARQ 197-114: A phase Ib safety trial evaluating ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC).

N. Senzer, L. Bolondi, L. Camacho, 2010 .

Exposure-Response Relationship to Assess the Risk of Neutropenia in Patients With Hepatocellular Carcinoma (HCC) Treated With Tivantinib

Raymond Miller, G. Abbadessa, H. Kastrissios, 2012 .

Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib.

J. Sosman, I. Puzanov, A. Adjei, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.